Redux is a revolutionary new anti-obesity drug that has just been approved (July 1996) by the FDA. It is the first weight management drug treatment to be launched in the United States in 20 years and is not addictive, unlike earlier drugs used for this purpose. Obesity Management and Redux includes a brief introduction which leads up to its discovery and includes an overview of new trends in obesity management. The book lists the pharmacological profile of the drug, given by experts involved in monitoring the effects of the drug on the brain neurotransmitters, as well as detailing the results (including safety data) of the various clinical trials.
- Covers all aspects of a revolutionary new drug
- Lists pharmacological profile of the drug
- Includes safety data
- Projects future trends in weight management
Inhaltsverzeichnis
1;Front Cover;1 2;Obesity Management and Redux TM;4 3;Copyright Page;5 4;Contents;14 5;Contributors;6 6;Preface;8 7;Introduction: History of Dexfenfluramine;12 8;Chapter 1. New Trends in the Management of Obesity in the United States;18 9;Chapter 2. The Impact of Obesity and the Introduction of Redux TM in the United States;24 10;Part I: Redux TM: Pharmacological Profile;28 10.1;Chapter 3. The Pharmacology of Dexfenfluramine;30 10.2;Chapter 4. Neurochemical Mode of Action of Drugs which Modify Feeding through the 5-HT System;34 10.3;Chapter 5. Dexfenfluramine: Biological Regulator of Risk Factors for Overeating;40 11;Part II: Methods for Assessing Neurochemical Changes and their Effect;50 11.1;Chapter 6. Advancement of Knowledge on Fenfluramine and Dexfenfluramine Effects on Brain Chemistry;52 11.2;Chapter 7. Reactive Gliosis as an Indicator of Neurotoxicity;60 11.3;Chapter 8. Dexfenfluramine Effects on Serotonin Neurons: A Long-term Immunohistochemical Analysis;66 11.4;Chapter 9. Behavioural and Other Functional Effects of Low and High Doses of Fenfluramine and Dexfenfluramine;74 11.5;Chapter 10. The Use of Pharmacokinetics in the Assessment of Dexfenfluramine Safety;82 12;Part III: ReduxTM: Therapeutic Efficacy;98 12.1;Chapter 11. Overview of the Clinical Data;100 12.2;Chapter 12. INDEX Study: Weight Data and Effects on Risk Factors and Comorbidities;104 12.3;Chapter 13. An 18-month Study of the Effects of Dexfenfluramine on Cognitive Function in Obese American Patients;110 12.4;Chapter 14. Fenfluramines, Obesity and Primary Pulmonary Hypertension: Risks and Benefits;116 12.5;Chapter 15. Overview of the Safety Data;122 13;Part IV: Benefit/Risk Ratio of the Treatment of Obesity;130 13.1;Chapter 16. Benefits and Risks of Treating Obesity;132 13.2;Chapter 17. Round Table Discussion;138